

SUPPLEMENTAL TABLE 1  
Patients tested by any malaria diagnostic test

Study (by setting)	Without mRDT interventions percentage numerator/ denominator	With mRDT interventions percentage numerator/ denominator	Odds ratio (95% CI)
Afgh1/a*	NA	NA	NA
Afgh1/b*	NA	NA	NA
Afgh1/c*	NA	NA	NA
Afgh2/a	0	98.8	∞†
	0/607	724/733	
Afgh2/b	0	100	∞†
	0/594	466/466	
Cam1/a‡	78.3	(1): 70.7	(1): 0.67
	313/400	494/699	(0.17, 2.66)
	–	(2): 79.5	(2): 1.08
	–	617/776	(0.28, 4.1)
Cam1/b‡	80.4	(1): 81.0	(1): 1.04
	226/281	757/933	(0.23, 4.7)
	–	(2): 77.8	(2): 0.85
	–	692/889	(0.15, 4.7)
Ghan1/a*	NA	NA	NA
Ghan1/b*	NA	NA	NA
Nige1§	1.7	(1): 29.9	(1): 25.5
	27/1,634	472/1,576	(7.5, 86)
		(2): 23.2	(2): 18.0
		428/1,844	(5.0, 64)
		(3): 15.8	(3): 11.2
		237/1,502	(3.08, 40)
Tanz1/a	7.3	48.4	12.0
	50/689	363/750	(4.2, 34.6)
Tanz1/b	12.7	43.1	5.2
	71/559	167/387	(2.26, 12.0)
Tanz1/c	31.3	71.5	5.5
	156/498	409/572	(2.30, 13.2)
Tanz2	0	(1): 39.1	∞†
	0/16,068	5,556/14,216	
		(2): 39.7	
		6,332/15,931	
		(3): 40.6	
		5,673/13,972	
Uga1	7.3	52.9	14.4
	15,285/210,758	117,350/221,755	(6.1, 33.9)
Uga2/a	0	96.0	∞†
	0/10,625	1,150/1,198	
Uga2/b	0	98.7	∞†
	0/2,444	7,736/7,840	
Uga3	0	97.3	∞†
	0/8,109	10,078/10,357	

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis.

† Odds ratio undefined; approaches infinity.

‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

|| Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

SUPPLEMENTAL TABLE 2  
Patients under age 5 years tested by any malaria diagnostic test

Study (by setting)	Without mRDT interventions		With mRDT interventions		Odds ratio (95% CI)
	Percentage numerator/denominator		Percentage numerator/denominator		
Afgh1/a*	NA		NA		NA
Afgh1/b*	NA		NA		NA
Afgh1/c*	NA		NA		NA
Afgh2/a	0.0		100.0		∞†
	0/47		76/76		
Afgh2/b	0.0		100.0		∞†
	0/20		15/15		
Cam1/a‡	85.2		(1): 64.4		(1): 0.32
	109/128		116/680		(0.04, 2.42)
			(2): 81.2		(2): 0.75
			190/234		(0.12, 4.7)
Cam1/b‡	85.2		(1): 84.0		(1): 0.91
	92/108		352/419		(0.18, 4.7)
			(2): 77.4		(2): 0.60
			291/376		(0.09, 3.85)
Ghan1/a*	NA		NA		NA
Ghan1/b*	NA		NA		NA
Nige1§	2.0		(1): 32.8		(1): 23.8
	6/299		38/116		(5.46, 103)
			(2): 30.9		(2): 21.9
			43/139		(4.96, 96.5)
			(3): 27.7		(3): 18.7
			38/137		(3.27, 107)
Tanz1/a	3.5		50.4		28.4
	14/405		259/514		(7.9, 102)
Tanz1/b	10.7		40.5		5.7
	33/308		100/247		(2.41, 13.3)
Tanz1/c	32.2		72.2		5.48
	103/320		268/371		(2.16, 13.9)
Tanz2	0.0		(1): 37.7		∞†
	0/6,559		1,981/5,270		-
	-		(2): 38.5		-
	-		2,346/6,101		-
	-		(3): 39.1		-
	-		1,820/4,649		-
Uga1	8.9		61.0		16.0
	5,774/64,825		40,978/67,159		(6.1, 42)
Uga2/a	0.0		96.0		∞†
	0/2,444		1,150/1,198		
Uga2/b	0.0		98.7		∞†
	0/10,625		7,736/1,198		
Uga3	0.0		98.3		∞†
	0/2,761		3,829/3,895		

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis.

† Odds ratio undefined; approaches infinity.

‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

|| Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

SUPPLEMENTAL TABLE 3  
Patients ages 5 years and older tested by any malaria diagnostic test

Study (by setting)	Without mRDT interventions	With mRDT interventions	Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a*	NA	NA	NA
Afgh1/b*	NA	NA	NA
Afgh1/c*	NA	NA	NA
Afgh2/a	0.0	98.6	∞†
	0/558	633/642	
Afgh2/b	0.0	100.0	∞†
	0/573	449/449	
Cam1/a‡	75.0	(1): 72.8	(1): 0.89
	204/272	378/519	(0.28, 2.90)
	–	(2): 78.8	(2): 1.24
	–	427/542	(0.37, 4.1)
Cam1/b‡	77.5	(1): 78.6	(1): 1.07
	134/173	403/513	(0.24, 4.7)
	–	(2): 78.2	(2): 1.04
	–	401/513	(0.20, 5.5)
Ghan1/a*	NA	NA	NA
Ghan1/b*	NA	NA	NA
Nige1§	1.5	(1): 29.5	(1): 26.9
	20/1,306	424/1,438	(7.3, 99)
	–	(2): 22.3	(2): 18.5
	–	375/1,679	(4.8, 71)
	–	(3): 14.3	(3): 10.7
	–	191/1,336	(2.85, 40)
Tanz1/a	12.7	44.1	5.4
	36/284	104/236	(1.77, 16.6)
Tanz1/b	15.1	47.9	5.1
	38/251	67/140	(1.92, 13.8)
Tanz1/c	29.8	70.1	5.5
	53/178	141/201	(2.21, 13.9)
Tanz2	0.0	(1): 40.0	∞†
	0/9,429	3,572/8,926	–
	–	(2): 40.6	–
	–	3,975/9,787	–
	–	(3): 41.4	–
	–	3,849/9,301	–
Uga1	6.5	49.9	14.4
	9,298/143,834	74,313/148,980	(6.23, 33.3)
Uga2/a	NA	NA	NA
Uga2/b	NA	NA	NA
Uga3	0.0	96.7	∞†
	0/5,625	6,156/6,369	

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis.

† Odds ratio undefined; approaches infinity.

‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

|| Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

SUPPLEMENTAL TABLE 4  
Patients prescribed ACT

Study (by setting)	Without mRDT interventions	With mRDT interventions	Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a	42.0 843/2,005	36.1 740/2,048	0.78 (0.68, 0.90)
Afgh1/b	24.4 126/517	20.1 106/527	0.78 (0.54, 1.13)
Afgh1/c	87.6 283/323	34.7 114/329	0.07 (0.02, 0.25)
Afgh2/a	77.9 471/605	26.6 188/708	0.10 (0.04, 0.25)
Afgh2/b	95.9 567/591	0.6 3/463	0.00 (0.00, 0.00)
Cam1/a*	79.5 314/395	(1): 43.5 294/676	(1): 0.20 (0.06, 0.61)
	–	(2): 37.9 286/754	(2): 0.16 (0.05, 0.52)
Cam1/b*	69.8 194/278	(1): 55.1 496/900	(1): 0.53 (0.28, 1.02)
	–	(2): 46.5 408/877	(2): 0.38 (0.17, 0.84)
Ghan1/a	63.7 1,210/1,900	62.3 1,180/1,893	0.94 (0.83, 1.08)
Ghan1/b	91.6 1,577/1,722	69.0 1,188/1,721	0.20 (0.07, 0.62)
Nige1†	56.9 934/1,642	(1): 49.3 717/1,453	(1): 0.74 (0.40, 1.35)
	–	(2): 45.4 828/1,823	(2): 0.63 (0.38, 1.03)
	–	(3): 54.2 808/1,409	(3): 0.90 (0.51, 1.57)
Tanz1/a‡	20.1 138/688	8.5 64/750	0.37 (0.17, 0.79)
Tanz1/b‡	49.2 275/559	25.5 99/388	0.35 (0.20, 0.61)
Tanz1/c‡	57.0 284/498	35.1 201/572	0.41 (0.24, 0.68)
Tanz2§	43.6 7,008/16,068	(1): 15.8 2,246/14,217	(1): 0.24 (0.15, 0.40)
	–	(2): 11.6 1,846/15,931	(2): 0.17 (0.10, 0.28)
	–	(3): 9.5 1,329/13,973	(3): 0.14 (0.08, 0.22)
Uga1	53.8 113,411/210,758	50.8 112,673/221,755	0.89 (0.67, 1.19)
Uga2/a	95.1 2,310/2,428	8.2 94/1,149	0.00 (0.00, 0.01)
Uga2/b	99.2 10,500/10,589	45.7 3,512/7,677	0.01 (0.00, 0.01)
Uga3	99.1 7,981/8,055	60.0 5,933/9,987	0.01 (0.01, 0.04)

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. Table presents the percentage of patients prescribed artemisinin-based combination therapy (ACT) except for: Afgh1 and Afgh2, where the percentage prescribed all antimalarials is presented to account for *Plasmodium vivax* treatment; and Nige1 without mRDT interventions only, where ACT or sulfadoxine-pyrimethamine (SP) is presented to reflect treatment practices at the time of data collection.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

‡ ACTs obtained by patient at the consultation (ACTs prescribed not available).

§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

SUPPLEMENTAL TABLE 5  
Patients in scenarios with mRDT interventions prescribed ACT, by malaria test result and not tested

Study (by setting)	Percentage patients prescribed an ACT (95% CI) numerator/denominator		
	Positive test result	Negative test result	Not tested
Afgh1/a*†‡	99.5 (97.9, 99.9) 552/555	12.6 (5.1, 27.7) 188/1,493	NA
Afgh1/b*†‡	–	19.2 (1.7, 76.0) 100/521	NA
Afgh1/c*†‡	–	34.5 (8.4, 75.1) 113/328	NA
Afgh2/a*‡	82.7 (63.3, 93.0) 163/197	4.0 (1.7, 9.2) 20/503	–
Afgh2/b*‡	–	0.4 (0.1, 1.3) 2/459	–
Cam1/a§	(1): 70.2 (37.3, 90.3) 33/47 (2): 79.6 (62.1, 90.3) 117/147	(1): 39.2 (13.4, 72.8) 167/426 (2): 24.6 (7.4, 57.2) 110/447	(1): 45.2 (28.7, 62.7) 89/197 (2): 35.3 (6.1, 82.0) 54/153
Cam1/b§	(1): 72.4 (58.2, 83.1) 254/351 (2): 70.1 (54.6, 82.0) 246/351	(1): 42.5 (29.3, 56.9) 157/369 (2): 18.3 (8.8, 34.2) 57/312	(1): 48.5 (40.5, 56.6) 81/167 (2): 51.6 (28.6, 73.9) 99/192
Ghan1/a†	98.2 (96.7, 99.0) 584/595	45.9 (43.2, 48.6) 596/1,298	(1): 45.0 (29.1, 61.9) 453/1,007 (2): 48.2 (38.3, 58.2) 674/1,399 (3): 56.9 (46.1, 67.1) 710/1,248
Ghan1/b†	97.5 (88.0, 99.5) 692/710	49.1 (1.0, 98.9) 496/1,011	NA
Nige1	(1): 74.4 (68.3, 79.6) 238/320 (2): 66.9 (48.4, 81.3) 95/142 (3): 60.2 (40.3, 77.2) 59/98	(1): 21.4 (10.3, 39.3) 24/112 (2): 21.6 (10.8, 38.5) 59/273 (3): 26.5 (11.3, 50.4) 36/136	NA
Tanz1/a¶	18.2 (7.0, 39.7) 14/77	4.9 (2.5, 9.6) 14/283	9.3 (4.9, 17.1) 36/387
Tanz1/b¶	94.4 (56.6, 99.5) 17/18	13.4 (8.1, 21.4) 20/149	28.2 (18.3, 40.8) 62/220
Tanz1/c¶	68.2 (53.4, 80.1) 131/192	5.1 (1.9, 12.9) 11/217	36.2 (17.3, 60.7) 59/163
Tanz2#	(1): 78.8 (64.6, 88.3) 1,146/1,455 (2): 80.2 (65.2, 89.8) 1,361/1,696 (3): 75.6 (50.3, 90.4) 944/1,249	(1): 17.0 (10.7, 26.0) 685/4,024 (2): 4.2 (1.8, 9.7) 191/4,541 (3): 3.6 (1.6, 8.2) 157/4,332	(1): 4.6 (2.2, 9.6) 401/8,660 (2): 3.0 (1.2, 7.0) 286/9,599 (3): 2.6 (1.2, 5.7) 218/8,299
Uga1	93.2 (89.7, 95.5) 75,808/81,359	2.7 (2.1, 3.5) 977/35,711	34.2 (23.1, 47.3) 35,717/104,405
Uga2/a	66.7 (41.7, 84.8) 24/36	3.1 (1.4, 6.4) 32/1,041	69.6 (48.7, 84.6) 32/46
Uga2/b	98.0 (96.9, 98.7) 3,318/3,385	1.1 (0.6, 1.8) 43/4,067	93.1 (80.4, 97.8) 95/102
Uga3	97.9 (96.5, 98.7) 5,551/5,670	1.2 (0.8, 1.9) 47/3,868	96.4 (91.4, 98.5) 269/279

ACT = artemisinin-based combination therapy; CI = confidence interval; mRDT = malaria rapid diagnostic tests; NA = not applicable.

\* Table presents the percentage of patients in scenarios with mRDT interventions prescribed ACT except for Afgh1 and Afgh2, where the percentage prescribed all antimalarials is presented to account for *Plasmodium vivax* treatment.

† Patients in the Afgh1 and Ghan1 studies were individually randomized to malaria diagnostic method; data are not included in this analysis because all patients in scenarios with mRDT interventions were tested.

‡ Data not included in the analysis when denominators were less than 10.

§ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

|| Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

¶ ACTs obtained by patient at the consultation; data on ACTs prescribed not available in Tanz1.

# Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

SUPPLEMENTAL TABLE 6  
Patients prescribed a systemic antibacterial

Study (by setting)	Without mRDT interventions		With mRDT interventions		Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a	38.1		40.8		1.12
	763/2,005		836/2,048		(0.97, 1.03)
Afgh1/b	73.3		78.9		1.36
	379/517		416/527		(0.76, 2.43)
Afgh1/c	14.2		57.1		8.0
	46/323		188/329		(2.70, 23.9)
Afgh2/a	18.2		54.1		5.3
	110/605		383/708		(2.28, 12.4)
Afgh2/b	48.4		68.5		2.32
	286/591		317/463		(0.85, 6.3)
Cam1/a*	72.8		(1): 78.5		(1): 1.36
	287/394		534/680		(0.68, 2.84)
	–		(2): 78.5		(2): 1.36
	–		595/757		(0.76, 2.43)
Cam1/b*	50.4		(1): 56.9		(1): 1.30
	140/278		510/897		(0.48, 3.53)
	–		(2): 47.3		(2): 0.89
	–		415/877		(0.35, 2.27)
Ghan1/a	30.8		32.1		1.06
	586/1,900		608/1,896		(0.92, 1.21)
Ghan1/b	28.0		32.6		1.24
	483/1,723		560/1,719		(0.90, 1.72)
Nige1†	23.2		(1): 13.6		(1): 0.52
	382/1,642		199/1,467		(0.29, 0.93)
	–		(2): 18.2		(2): 0.73
	–		330/1,817		(0.46, 1.17)
	–		(3): 15.1		(3): 0.59
	–		223/1,474		(0.34, 1.03)
Tanz1/a‡	29.7		44.7		1.92
	204/688		335/749		(1.20, 3.08)
Tanz1/b‡	35.2		56.4		2.38
	197/688		219/388		(1.54, 3.68)
Tanz1/c‡	33.1		49.0		1.94
	165/498		280/572		(1.32, 3.83)
Tanz24§	61.5		(1): 73.2		(1): 1.71
	9,875/16,068		10,407/14,217		(1.25, 2.35)
	–		(2): 75.4		(2): 1.92
	–		12,014/15,931		(1.42, 2.61)
	–		(3): 70.5		(3): 1.50
	–		9,853/13,973		(1.19, 1.89)
Uga1	53.7		57.9		1.18
	113,102/210,758		128,406/221,755		(0.79, 1.77)
Uga2/a	NA		NA		NA
Uga2/b	NA		NA		NA
Uga3	19.4		34.9		2.24
	48/248		87/249		(1.41, 3.54)

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

‡ Any antibacterials obtained by patients at the consultation; data on systemic antibacterials prescribed not available in Tanz1.

§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

SUPPLEMENTAL TABLE 7

Patients in scenarios with mRDT interventions prescribed a systemic antibacterial, by malaria test result and not tested

Study (by setting)	Percentage prescribed an antibacterial (95% CI) numerator/denominator		
	Positive test result	Negative test result	Not tested
Aghg1/a*	3.6 (1.8, 7.1) 20/555	54.7 (37.9, 70.4) 816/1,493	NA
Afgh1/b*†	–	70.7 (60.0, 91.1) 415/521	NA
Afgh1/c*†	–	57.3 (23.0, 85.8) 188/328	NA
Afgh2/a†	8.1 (4.8, 13.5) 16/197	72.8 (49.9, 87.8) 366/503	–
Afgh2/b†	–	68.8 (41.9, 87.1) 316/459	–
Cam1/a‡	(1): 66.0 (48.2, 80.1) 31/47 (2): 74.7 (65.3, 82.2) 109/146	(1): 79.9 (65.9, 89.1) 341/427 (2): 83.1 (75.4, 88.9) 375/451	(1): 80.0 (57.5, 92.2) 160/200 (2): 69.3 (64.6, 73.6) 106/153
Cam1/b‡	(1): 58.0 (42.4, 72.2) 203/350 (2): 43.7 (31.7, 56.5) 153/350	(1): 63.5 (46.9, 77.4) 203/350 (2): 52.6 (45.1, 60.0) 164/312	(1): 42.5 (25.2, 61.9) 71/167 (2): 47.9 (28.2, 68.3) 92/192
Ghan1/a*	14.6 (12.0, 17.7) 87/595	40.0 (37.4, 42.7) 521/1,301	NA
Ghan1/b*	18.0 (11.1, 27.9) 128/710	42.8 (12.4, 79.9) 432/1,009	NA
Nige1§	(1): 17.5 (13.3, 22.7) 55/314 (2): 14.9 (8.5, 24.7) 21/141 (3): 20.2 (8.5, 41.0) 20/99	(1): 26.1 (12.2, 47.4) 29/111 (2): 13.3 (6.7, 24.6) 37/279 (3): 21.6 (13.9, 32.2) 29/134	(1): 11.1 (5.6, 20.9) 114/1,026 (2): 19.5 (14.9, 25.2) 271/1,388 (3): 13.9 (8.9, 21.3) 172/1,233
Tanz1/a	31.6 (17.3, 50.5) 24/76	53.0 (42.2, 63.6) 150/283	41.3 (30.4, 52.2) 160/387
Tanz1/b	44.4 (11.4, 83.3) 8/18	58.4 (47.2, 68.8) 87/149	56.4 (44.7, 67.4) 124/220
Tanz1/c	30.7 (20.8, 42.9) 59/192	61.8 (50.4, 71.9) 134/217	53.4 (39.4, 66.8) 87/163
Tanz2¶	(1): 26.5 (13.4, 45.8) 386/1,455 (2): 36.1 (25.4, 48.3) 612/1,696 (3): 26.3 (18.0, 36.6) 328/1,249	(1): 74.2 (67.1, 80.2) 2,985/4,024 (2): 77.7 (69.9, 83.9) 3,527/4,541 (3): 74.7 (69.2, 79.6) 3,238/4,332	(1): 80.6 (75.5, 84.8) 6,979/6,880 (2): 81.3 (75.1, 86.2) 7,800/9,599 (3): 74.9 (68.6, 80.3) 6,214/8,299
Uga1	40.5 (30.6, 51.2) 32,935/81,359	69.3 (65.3, 73.0) 24,737/35,711	66.3 (60.5, 71.7) 69,178/104,405
Uga2/a#	NA	NA	NA
Uga2/b#	NA	NA	NA
Uga3†	23.6 (16.3, 33.0) 30/127	46.0 (37.7, 54.6) 52/113	–

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Patients in the Afgh1 and Ghan1 studies were individually randomized to malaria diagnostic method; data are not included in this analysis because all patients in scenarios with mRDT interventions were tested.

† Data not included in the analysis when denominators were less than 10.

‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

|| Any antibacterials obtained by patients at the consultation; data on systemic antibacterials prescribed not available in Tanz1.

¶ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

# Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

SUPPLEMENTAL TABLE 8  
Patients prescribed an antimalarial and an antibacterial

Study (by setting)	Without mRDT interventions	With mRDT interventions	Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a	1.2 25/2,005	1.5 30/2,048	1.18 (0.66, 2.11)
Afgh1/b	10.6 55/517	8.7 46/527	0.80 (0.54, 1.19)
Afgh1/c	4.6 15/323	4.3 14/329	0.91 (0.50, 1.68)
Afgh2/a	47.4 280/51	0.2 1/463	0.00 (0.00, 0.02)
Afgh2/b	16.7 101/605	3.1 22/708	0.16 (0.06, 0.40)
Cam1/a*	66.1 259/392	(1): 37.7 253/672	(1): 0.31 (0.15, 0.65)
	–	(2): 32.8 247/753	(2): 0.25 (0.10, 0.61)
Cam2/b*	43.9 122/278	(1): 40.1 359/896	(1): 0.85 (0.33, 2.24)
	–	(2): 28.1 247/875	(2): 0.50 (0.19, 1.31)
Ghan1/a	12.3 234/1,899	12.4 235/1,893	1.01 (0.83, 1.22)
Ghan1/b	23.8 410/1,722	15.3 263/1,719	0.58 (0.32, 1.04)
Nige1†	14.7 241/1,642	(1): 12.3 174/1,459	(1): 0.81 (0.48, 1.39)
	–	(2): 14.0 253/1,805	(2): 0.95 (0.58, 1.55)
	–	(3): 11.9 175/1,472	(3): 0.78 (0.51, 1.21)
Tanz1/a‡	6.8 47/688	4.1 31/749	0.59 (0.27, 1.28)
Tanz1/b‡	18.2 102/559	12.9 50/388	0.66 (0.36, 1.22)
Tanz1/c‡	15.5 77/498	14.7 84/572	0.94 (0.49, 1.82)
Tanz2§	24.2 3,891/16,068	(1): 6.9 974/14,217	(1): 0.23 (0.14, 0.37)
	–	(2): 5.7 908/15,931	(2): 0.19 (0.12, 0.31)
	–	(3): 3.6 500/13,973	(3): 0.12 (0.07, 0.19)
Uga1	23.8 50,098/210,758	23.5 52,212/221,755	0.99 (0.59, 1.65)
Uga2/a	NA	NA	NA
Uga2/b	NA	NA	NA
Uga3	19.4 48/248	14.2 33/233	0.69 (0.45, 1.06)

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

‡ Antimalarials and any antibacterials obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.



SUPPLEMENTAL TABLE 9  
Patients prescribed an antimalarial or an antibacterial

Study (by setting)	Without mRDT interventions	With mRDT interventions	Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a	78.9 1,581/2,005	75.5 1,546/2,048	0.83 (0.74, 0.93)
Afgh1/b	87.0 450/517	90.3 476/527	1.39 (0.73, 2.66)
Afgh1/c	97.2 314/323	87.5 288/329	0.20 0.08, 0.48)
Afgh2/a	97.0 573/591	68.9 319/463	0.07 (0.03, 0.19)
Afgh2/b	79.3 480/605	77.5 549/708	0.90 (0.32, 2.56)
Cam1/a*	94.2 372/394	(1): 92.5 629/680	(1): 0.73 (0.19, 2.76)
	–	(2): 90.9 687/757	(2): 0.59 (0.16, 2.14)
Cam1/b*	97.1 270/278	(1): 88.1 790/897	(1): 0.22 (0.10, 0.49)
	–	(2): 79.8 700/877	(2): 0.12 (0.05, 0.27)
Ghan1/a	82.9 1,575/1,899	82.2 1,557/1,894	0.95 (0.80, 1.12)
Ghan1/b	97.0 1,670/1,722	85.7 1,501/1,719	0.21 (0.10, 0.48)
Nige1†	84.5 1,369/1,642	(1): 81.7 1,158/1,460	(1): 0.82 (0.37, 1.79)
	–	(2): 80.4 1,451/1,805	(2): 0.75 (0.41, 1.37)
	–	(3): 86.8 1,278/1,473	(3): 1.20 (0.49, 2.93)
Tanz1/a‡	46.2 318/688	52.7 395/749	1.30 (0.81, 2.09)
Tanz1/b‡	68.7 384/559	70.4 273/388	1.08 (0.61, 1.93)
Tanz1/c‡	79.1 394/498	72.2 413/572	0.69 (0.40, 1.16)
Tanz2§	87.9 14,125/16,068	(1): 85.4 12,146/14,217	(1): 0.81 (0.61, 1.08)
	–	(2): 84.4 13,446/15,931	(2): 0.74 (0.55, 1.01)
	–	(3): 79.0 11,032/13,973	(3): 0.52 (0.40, 0.66)
Uga1	85.5 180,106/210,758	87.0 192,831/221,755	1.13 (0.67, 1.91)
Uga2/a	NA	NA	NA
Uga2/b	NA	NA	NA
Uga3	100.0 248/248	78.7 188/239	0.00¶

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

‡ Antimalarials and any antibacterials obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

¶ Odds ratio undefined; approaches zero.

SUPPLEMENTAL TABLE 10  
Patients prescribed a systemic antihelminthic, and patients prescribed a systemic antifungal

Study (by setting)	Antihelminthics		Antifungals	
	Without mRDT interventions	With mRDT interventions	Without mRDT interventions	With mRDT interventions
	Percentage numerator/denominator	Percentage numerator/denominator	Percentage numerator/denominator	Percentage numerator/denominator
Afgh1/a	0.5 (10/2,005)	0.3 (7/2,048)	0 (0/2,005)	0 (0/2,048)
Afgh1/b	0.8 (4/517)	0.8 (4/527)	0 (0/517)	0 (0/527)
Afgh1/c	0.0 (0/323)	0.3 (1/329)	0 (0/323)	0 (0/329)
Afgh2/a*	NA	NA	NA	NA
Afgh2/b*	NA	NA	NA	NA
Cam1/a†	11.4 (45/394)	(1): 4.3 (29/680)	0.8 (3/394)	(1): 1.2 (8/680)
	–	(2): 8.5 (76/897)	–	(2): 1.9 (17/897)
	–		–	
Cam1/b†	8.3 (23/278)	(1): 7.1 (54/757)	1.4(4/278)	(1): 0.4 (3/757)
		(2): 10.4 (91/877)		(2): 2.6 (23/877)
Ghan1/a	31.6 (600/1,900)	33.3 (631/1,896)	0.6 (11/1,900)	0.7 (13/1,896)
Ghan1/b	8.6 (149/1,723)	11.3 (195/1,719)	0.1 (1/1,723)	0.3 (6/1,719)
Nige1‡	2.0 (33/1,642)	(1): 0.3 (4/1,588)	0.1 (1/1642)	(1): 0 (0/1,588)
		(2): 0.3 (5/1,850)		(2): 0 (0/1,850)
		(3): 1.3 (19/1,508)		(3): 0 (0/1,508)
Tanz1/a§	1.7 (12/688)	4.5 (34/749)	0 (0/688)	0 (0/749)
Tanz1/b§	3.2 (18/559)	7.2 (28/388)	0 (0/559)	0 (0/388)
Tanz1/c§	2.2 (11/498)	3.1 (18/572)	0 (0/498)	0 (0/572)
Tanz2*	NA	(1) NA	NA	(1) NA
		(2) NA		(3) NA
		(4) NA		(2) NA
Uga1	14.6 (30,865/210,758)	16.1 (35,683/221,755)	0.1 (195/210,758)	0.1 (318/221,755)
Uga2/a*	NA	NA	NA	NA
Uga2/b*	NA	NA	NA	NA
Uga3	4.0 (10/248)	5.2 (13/249)	0 (0/248)	0 (0/249)

mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Data on systemic antihelminthics and antifungals prescribed were not collected from Afgh2, Tanz2, and Uga2.

† Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

‡ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

§ Systemic antihelminthics and antifungals obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

SUPPLEMENTAL TABLE 11  
Patients prescribed an antipyretic without an antimalarial or an antibiotic

Study (by setting)	Without mRDT interventions	With mRDT interventions	Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a	19.7 395/2,005	22.7 464/2,048	1.19 (1.07, 1.34)
Afgh1/b	10.8 56/517	8.2 43/527	0.73 (0.35, 1.53)
Afgh1/c	2.8 9/323	12.2 40/329	4.8 (2.16, 10.8)
Afgh2/a	1.2 7/591	17.3 80/463	17.4 (3.41, 89)
Afgh2/b	0.3 2/605	11.6 82/708	39.5 (12.9, 121)
Cam1/a*	0.5 2/392	(1): 4.2 28/671	(1): 8.5 (1.34, 54)
	–	(2): 7.1 53/749	(2): 14.9 (2.44, 90)
	–	(1): 3.7 33/895	(1): 2.09 (0.66, 6.7)
Cam1/b*	1.8 5/278	(1): 3.7 33/895	(1): 2.09 (0.66, 6.7)
	–	(2): 5.8 51/874	(2): 3.38 (1.01, 11.4)
	–	(1): 3.7 33/895	(1): 2.09 (0.66, 6.7)
Ghan1/a	12.6 239/1,899	14.3 271/1,893	1.16 (0.96, 1.40)
Ghan1/b	2.4 42/1,722	10.2 176/1,719	4.6 (1.98, 10.5)
Nige1†	7.6 138/1,642	(1): 3.1 44/1,459	(1): 0.39 (0.17, 0.89)
	–	(2): 8.9 161/1,825	(2): 1.19 (0.66, 2.13)
	–	(3): 3.9 58/1,489	(3): 0.50 (0.18, 1.39)
	–	18.8 141/749	0.75 (0.46, 1.23)
	–	12.1 47/388	0.95 (0.49, 1.83)
Tanz1/a‡	23.7 163/688	18.8 141/749	0.75 (0.46, 1.23)
Tanz1/b‡	12.7 71/559	12.1 47/388	0.95 (0.49, 1.83)
Tanz1/c‡	9.4 47/498	18.2 104/572	2.13 (1.25, 3.64)
Tanz2§	6.4 (1,020/15,953)	(1): 10.9 1,545/14,217	(1): 1.78 (1.32, 2.41)
	–	(2): 11.4 1,818/15,931	(2): 1.89 (1.34, 2.65)
	–	(3): 14.1 1,964/13,973	(3): 2.39 (1.89, 3.04)
	–	8.4 18,630/221,755	0.79 (0.43, 1.45)
Uga1	10.1 21,803/210,758	8.4 18,630/221,755	0.79 (0.43, 1.45)
Uga2/a	NA	NA	NA
Uga2/b	NA	NA	NA
Uga3	0.0 0/248	14.6 34/233	∞¶

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

‡ Antipyretics obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

¶ Odds ratio undefined; approaches infinity.

SUPPLEMENTAL TABLE 12  
Patients prescribed three or more medicines

Study (by setting)	Without mRDT interventions	With mRDT interventions	Odds ratio (95% CI)
	Percentage numerator/denominator	Percentage numerator/denominator	
Afgh1/a	16.1 322/2,005	15.1 309/2,048	0.93 (0.80, 1.08)
Afgh1/b	36.0 186/517	34.7 183/527	0.95 (0.85, 1.06)
Afgh1/c	60.1 194/323	38.3 126/329	0.41 (0.19, 0.92)
Afgh2/a	62.3 368/591	3.2 15/463	0.02 (0.01, 0.05)
Afgh2/b	28.1 170/605	10.2 72/708	0.29 (0.10, 0.88)
Cam1/a*	87.5 350/400	(1): 82.3 575/699	(1): 0.66 (0.28, 1.58)
	–	(2): 79.8	(2): 0.57 (0.26, 1.22)
Cam1/b*	–	621/778	
	78.6 221/281	(1): 71.5 667/933	(1): 0.68 (0.33, 1.41)
	–	(2): 61.3	(2): 0.43 (0.19, 0.98)
	–	546/891	
Ghan1/a	91.8 (1,751/1,907)	91.4 (1,740/1,904)	0.95 (0.75, 1.19)
Ghan1/b	90.3 (1,559/1,727)	88.2 (1,521/1,725)	0.80 (0.61, 1.07)
Nige1†	60.8 965/1,587	(1): 56.4 896/1,588	(1): 0.83 (0.45, 1.54)
	–	(2): 53.2	(2): 0.73 (0.39, 1.38)
	–	985/1,850	
	–	(3): 57.1	(3): 0.86 (0.51, 1.44)
	–	861/1,508	
Tanz1/a‡	13.8 95/688	18.6 139/748	1.42 (0.80, 2.53)
Tanz1/b‡	24.2 143/498	30.7 119/388	1.39 (0.90, 2.14)
Tanz1/c‡	28.7 143/498	26.6 152/571	0.90 (0.52, 1.57)
Tanz2§	NA	(1): NA (2): NA (3): NA	(1): NA (2): NA (3): NA
Uga1	50.9 107,348/210,758	52.2 115,850/221,755	1.05 (0.66, 1.68)
Uga2/a	NA	NA	NA
Uga2/b	NA	NA	NA
Uga3	54.0 134/248	60.2 150/249	1.29 (0.80, 2.07)

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

‡ Medicines obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

§ Tanz2 did not record data on all medications prescribed, so this study is not included in Figure 4D.

|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

SUPPLEMENTAL TABLE 13  
Patients referred to another care provider or health facility

Study (by setting)	Without mRDT interventions		With mRDT interventions		Odds ratio (95% CI)
	Percentage numerator/denominator		Percentage numerator/denominator		
Afgh1/a	0.1		0.0		0.33 (0.03, 3.47)
	3/2,005		1/2,048		
Afgh1/b	0.0		0.0		–
	0/323		0/329		
Afgh1/c	0.2		0.4		1.97 (0.13, 29.1)
	1/517		2/527		
Afgh2/a	29.0		64.2		4.4 (2.28, 8.5)
	172/594		299/466		
Afgh2/b	23.9		15.7		0.59 (0.19, 1.81)
	145/607		115/732		
Cam1*	0.8		(1): 0.9		(1): 1.15 (0.28, 4.7)
	3/399		6/695		(2): 1.92 (0.47, 7.8)
	–		11/769		
Cam2*	0.4		(1): 1.3		(1): 3.76 (0.70, 20.1)
	1/280		12/903		(2): 10.0 (1.38, 73)
	–		(2): 3.5		
	–		30/864		
Ghan1/a†	NA		NA		NA
Ghan1/b†	NA		NA		NA
Nige1‡	1.0		(1): 1.9		(1): 1.88 (0.59, 5.9)
	17/1,630		30/1,548		(2): 1.63 (0.61, 4.4)
	–		(2): 1.7		
	–		31/1,833		(3): 3.77 (0.89, 15.93)
	–		(3): 3.8		
	–		57/1,491		
Tanz1/a†	NA		NA		NA
Tanz1/b†	NA		NA		NA
Tanz1/c†	NA		NA		NA
Tanz2†§	NA		(1): NA		(1): NA
			(2): NA		(2): NA
			(3): NA		(3): NA
Uga1†	NA		NA		NA
Uga2/b	1.0		35.1		52 (34.8, 77)
	109/10,599		821/1,168		
Uga2/a	13.1		70.3		15.8 (9.3, 27)
	314/2,404		2,706/77,16		
Uga3	3.5		12.1		3.82 (0.82, 17.8)
	279/8,039		1,234/10,226		

CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable.

\* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

† Ghan1, Tanz1, Tanz2, and Uga1 did not record data on referral.

‡ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.